2025 Q4 -tulosraportti
28 päivää sitten
‧49 min
8,00 NOK/osake
Irtoamispäivä 7.5.
2,88%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·20.3.Have started looking a bit at Medistim and think it seems like a solid niche case with high quality, especially regarding margins and recurring revenues. At the same time, I'm left with the question of how much of this is already priced in. How do you view further growth, especially internationally, and any potential triggers going forward?
·1 päivä sittenMedistim is a classic growth case in an industry with limited cyclical sensitivity. The underlying market for cardiovascular surgery is growing, driven by demographics (we are getting older) and increased treatment capacity globally. At the same time, the company has over time shown that they not only follow the market, they gain market share. At the same time, it is worth understanding how they make money. This is not a pure equipment case within medtech. Once a system is installed, it generates recurring revenue through consumables, especially flow probes and procedures (smartcards) used in each operation. Around 70 % of revenues are recurring. This means that growth is largely driven by clinical use, not just the sale of systems. (it also means there is a good base in current earnings) The question is therefore not whether the company grows, but what growth one should assume going forward. Medistim has delivered impressive and accelerating growth for over 20 years: around 10 % annual EPS-growth since 2005, 12–13 % in the last ten years, and 17 % in the period 2020–2025 (54% in 2025). At today's price, the stock is valued at around 25 times earnings, while the dividend yield is just under 4 %, i.e., not far from the risk-free rate. The valuation therefore boils down to one thing: what growth one believes in going forward (in addition to what the market generally is willing to pay for growth..). A P/E of ~25x in my view implies something in the range of 10–12 % annual growth. Given that, the stock appears approximately fairly priced today. If, however, one believes that the company manages to maintain closer to 15 % growth, a clear upside potential towards 300 kroner and upwards begins to open up. If one believes in 20% annual growth, the stock will probably rise back to ATH from 2021: 400kr+. In the short term, there are some obvious “headwinds”. Currency can have a negative impact in 2026, and not least: Q1 2025 was extremely strong, which provides a high comparison base, where it will take a lot to deliver the same year/year-growth now in Q1. This can quickly lead to some weak headlines, even if the underlying development is perfectly fine. For my part, I have great faith in the company and believe growth will be closer to 15% going forward, then the upside is significant.
18.3.18.3.Intertrade Shipping AS, which is partly owned and controlled by Øyvin A. Brøymer, has today purchased 50,000 shares in Medistim ASA at NOK 208 per share, - totaling NOK 10,400,000. Øyvin A. Brøymer is the chairman of the board in Medistim ASA. After the purchase, Intertrade Shipping AS owns 1,015,001 shares in the company. Fløtemarken AS, which is a 100% owned company of Intertrade Shipping AS, additionally owns 1,285,000 shares in Medistim ASA. In total, Øyvin A. Brøymer controls 2,300,001 shares in Medistim ASA after the purchased.
13.3.13.3.MEDI: Intertrade Shipping AS purchases Medistim shares Close i dag kl. 14:14 ∙ Oslo Børs Medistim Intertrade Shipping AS, which is partly-owned and controlled by Øyvin A. Brøymer, has today purchased 29,266 shares in Medistim ASA at NOK 200.5776 per share, - totaling NOK 5,875,974.14. Øyvin A. Brøymer is the chairman of the board in Medistim ASA. After the purchase, Intertrade Shipping AS owns 965,001 shares in the company. Fløtemarken AS, which is a 100% owned company of Intertrade Shipping AS, additionally owns 1,285,000 shares in Medistim ASA. In total, Øyvin A. Brøymer controls 2,250,001 shares in Medistim ASA after the purchase.
·13.3.I would like to know the reason for selling below 200 kr from some of those who are doing it now, after the company delivered stellar figures in Q4, a record year last year, and the highest dividend to date. I would appreciate hearing the reason for that, unless it's personal reasons, of course.- ·12.3.This stock seems to be a somewhat forgotten stock. Very rarely mentioned in the financial press, and very little commented on in forums. This gem has been on the stock exchange for a long time, delivers good results with a record in Q4 and for the full year 2025. Quite decent dividend (8 kr /approx 4%) and an attractive portfolio of own products for hospitals and healthcare enterprises. This is not something AI can destroy, and this is also not a market that will cease to exist; on the contrary, healthcare will likely only grow due to an aging population. After the Q4 figures, it rose so much that I was tempted to sell out at 230, but have now bought back my shares again, at a price I find very favorable. No reason for Medistim to fall as it has done after the figures other than that it is an unsettled market. If one is long-term, one sits well in this fine stock, in my opinion.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
28 päivää sitten
‧49 min
8,00 NOK/osake
Irtoamispäivä 7.5.
2,88%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·20.3.Have started looking a bit at Medistim and think it seems like a solid niche case with high quality, especially regarding margins and recurring revenues. At the same time, I'm left with the question of how much of this is already priced in. How do you view further growth, especially internationally, and any potential triggers going forward?·1 päivä sittenMedistim is a classic growth case in an industry with limited cyclical sensitivity. The underlying market for cardiovascular surgery is growing, driven by demographics (we are getting older) and increased treatment capacity globally. At the same time, the company has over time shown that they not only follow the market, they gain market share. At the same time, it is worth understanding how they make money. This is not a pure equipment case within medtech. Once a system is installed, it generates recurring revenue through consumables, especially flow probes and procedures (smartcards) used in each operation. Around 70 % of revenues are recurring. This means that growth is largely driven by clinical use, not just the sale of systems. (it also means there is a good base in current earnings) The question is therefore not whether the company grows, but what growth one should assume going forward. Medistim has delivered impressive and accelerating growth for over 20 years: around 10 % annual EPS-growth since 2005, 12–13 % in the last ten years, and 17 % in the period 2020–2025 (54% in 2025). At today's price, the stock is valued at around 25 times earnings, while the dividend yield is just under 4 %, i.e., not far from the risk-free rate. The valuation therefore boils down to one thing: what growth one believes in going forward (in addition to what the market generally is willing to pay for growth..). A P/E of ~25x in my view implies something in the range of 10–12 % annual growth. Given that, the stock appears approximately fairly priced today. If, however, one believes that the company manages to maintain closer to 15 % growth, a clear upside potential towards 300 kroner and upwards begins to open up. If one believes in 20% annual growth, the stock will probably rise back to ATH from 2021: 400kr+. In the short term, there are some obvious “headwinds”. Currency can have a negative impact in 2026, and not least: Q1 2025 was extremely strong, which provides a high comparison base, where it will take a lot to deliver the same year/year-growth now in Q1. This can quickly lead to some weak headlines, even if the underlying development is perfectly fine. For my part, I have great faith in the company and believe growth will be closer to 15% going forward, then the upside is significant.
- 18.3.18.3.Intertrade Shipping AS, which is partly owned and controlled by Øyvin A. Brøymer, has today purchased 50,000 shares in Medistim ASA at NOK 208 per share, - totaling NOK 10,400,000. Øyvin A. Brøymer is the chairman of the board in Medistim ASA. After the purchase, Intertrade Shipping AS owns 1,015,001 shares in the company. Fløtemarken AS, which is a 100% owned company of Intertrade Shipping AS, additionally owns 1,285,000 shares in Medistim ASA. In total, Øyvin A. Brøymer controls 2,300,001 shares in Medistim ASA after the purchased.
- 13.3.13.3.MEDI: Intertrade Shipping AS purchases Medistim shares Close i dag kl. 14:14 ∙ Oslo Børs Medistim Intertrade Shipping AS, which is partly-owned and controlled by Øyvin A. Brøymer, has today purchased 29,266 shares in Medistim ASA at NOK 200.5776 per share, - totaling NOK 5,875,974.14. Øyvin A. Brøymer is the chairman of the board in Medistim ASA. After the purchase, Intertrade Shipping AS owns 965,001 shares in the company. Fløtemarken AS, which is a 100% owned company of Intertrade Shipping AS, additionally owns 1,285,000 shares in Medistim ASA. In total, Øyvin A. Brøymer controls 2,250,001 shares in Medistim ASA after the purchase.
- ·13.3.I would like to know the reason for selling below 200 kr from some of those who are doing it now, after the company delivered stellar figures in Q4, a record year last year, and the highest dividend to date. I would appreciate hearing the reason for that, unless it's personal reasons, of course.
- ·12.3.This stock seems to be a somewhat forgotten stock. Very rarely mentioned in the financial press, and very little commented on in forums. This gem has been on the stock exchange for a long time, delivers good results with a record in Q4 and for the full year 2025. Quite decent dividend (8 kr /approx 4%) and an attractive portfolio of own products for hospitals and healthcare enterprises. This is not something AI can destroy, and this is also not a market that will cease to exist; on the contrary, healthcare will likely only grow due to an aging population. After the Q4 figures, it rose so much that I was tempted to sell out at 230, but have now bought back my shares again, at a price I find very favorable. No reason for Medistim to fall as it has done after the figures other than that it is an unsettled market. If one is long-term, one sits well in this fine stock, in my opinion.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
2025 Q4 -tulosraportti
28 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
8,00 NOK/osake
Irtoamispäivä 7.5.
2,88%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·20.3.Have started looking a bit at Medistim and think it seems like a solid niche case with high quality, especially regarding margins and recurring revenues. At the same time, I'm left with the question of how much of this is already priced in. How do you view further growth, especially internationally, and any potential triggers going forward?·1 päivä sittenMedistim is a classic growth case in an industry with limited cyclical sensitivity. The underlying market for cardiovascular surgery is growing, driven by demographics (we are getting older) and increased treatment capacity globally. At the same time, the company has over time shown that they not only follow the market, they gain market share. At the same time, it is worth understanding how they make money. This is not a pure equipment case within medtech. Once a system is installed, it generates recurring revenue through consumables, especially flow probes and procedures (smartcards) used in each operation. Around 70 % of revenues are recurring. This means that growth is largely driven by clinical use, not just the sale of systems. (it also means there is a good base in current earnings) The question is therefore not whether the company grows, but what growth one should assume going forward. Medistim has delivered impressive and accelerating growth for over 20 years: around 10 % annual EPS-growth since 2005, 12–13 % in the last ten years, and 17 % in the period 2020–2025 (54% in 2025). At today's price, the stock is valued at around 25 times earnings, while the dividend yield is just under 4 %, i.e., not far from the risk-free rate. The valuation therefore boils down to one thing: what growth one believes in going forward (in addition to what the market generally is willing to pay for growth..). A P/E of ~25x in my view implies something in the range of 10–12 % annual growth. Given that, the stock appears approximately fairly priced today. If, however, one believes that the company manages to maintain closer to 15 % growth, a clear upside potential towards 300 kroner and upwards begins to open up. If one believes in 20% annual growth, the stock will probably rise back to ATH from 2021: 400kr+. In the short term, there are some obvious “headwinds”. Currency can have a negative impact in 2026, and not least: Q1 2025 was extremely strong, which provides a high comparison base, where it will take a lot to deliver the same year/year-growth now in Q1. This can quickly lead to some weak headlines, even if the underlying development is perfectly fine. For my part, I have great faith in the company and believe growth will be closer to 15% going forward, then the upside is significant.
- 18.3.18.3.Intertrade Shipping AS, which is partly owned and controlled by Øyvin A. Brøymer, has today purchased 50,000 shares in Medistim ASA at NOK 208 per share, - totaling NOK 10,400,000. Øyvin A. Brøymer is the chairman of the board in Medistim ASA. After the purchase, Intertrade Shipping AS owns 1,015,001 shares in the company. Fløtemarken AS, which is a 100% owned company of Intertrade Shipping AS, additionally owns 1,285,000 shares in Medistim ASA. In total, Øyvin A. Brøymer controls 2,300,001 shares in Medistim ASA after the purchased.
- 13.3.13.3.MEDI: Intertrade Shipping AS purchases Medistim shares Close i dag kl. 14:14 ∙ Oslo Børs Medistim Intertrade Shipping AS, which is partly-owned and controlled by Øyvin A. Brøymer, has today purchased 29,266 shares in Medistim ASA at NOK 200.5776 per share, - totaling NOK 5,875,974.14. Øyvin A. Brøymer is the chairman of the board in Medistim ASA. After the purchase, Intertrade Shipping AS owns 965,001 shares in the company. Fløtemarken AS, which is a 100% owned company of Intertrade Shipping AS, additionally owns 1,285,000 shares in Medistim ASA. In total, Øyvin A. Brøymer controls 2,250,001 shares in Medistim ASA after the purchase.
- ·13.3.I would like to know the reason for selling below 200 kr from some of those who are doing it now, after the company delivered stellar figures in Q4, a record year last year, and the highest dividend to date. I would appreciate hearing the reason for that, unless it's personal reasons, of course.
- ·12.3.This stock seems to be a somewhat forgotten stock. Very rarely mentioned in the financial press, and very little commented on in forums. This gem has been on the stock exchange for a long time, delivers good results with a record in Q4 and for the full year 2025. Quite decent dividend (8 kr /approx 4%) and an attractive portfolio of own products for hospitals and healthcare enterprises. This is not something AI can destroy, and this is also not a market that will cease to exist; on the contrary, healthcare will likely only grow due to an aging population. After the Q4 figures, it rose so much that I was tempted to sell out at 230, but have now bought back my shares again, at a price I find very favorable. No reason for Medistim to fall as it has done after the figures other than that it is an unsettled market. If one is long-term, one sits well in this fine stock, in my opinion.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt